Yesterday the Food and Drug Administration (FDA) approved Spravato (esketamine) nasal spray to be us...

Intranasal esketamine—a derivative of ketamine—appears to rapidly reduce symptoms of depression, inc...

A subset of individuals 65 years or older with treatment-resistant depression who took a new oral an...

In patients with treatment-resistant depression who responded to intranasal esketamine plus an antid...

An independent advisory panel to the Food and Drug Administration (FDA) on Tuesday endorsed the eske...

Intranasal esketamine taken twice weekly can rapidly reduce symptoms of people with treatment-resist...